For the year ending 2025-12-31, RYTM had -$34,778K decrease in cash & cash equivalents over the period. -$116,628K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenues | 189,757 |
| Cost of sales | 19,492 |
| Global headcount expense | 172,648 |
| Preclinical, clinical and development expense | 87,322 |
| Commercial & medical affairs | 66,963 |
| Corporate, general & administrative | 35,348 |
| Other segment expenses | 0 |
| Other (income) expense, net | -1,264 |
| Interest (income) expense, net | -5,290 |
| Income taxes | 497 |
| Net loss | -196,539 |
| Stock-based compensation expense | 66,818 |
| Depreciation and amortization | 1,338 |
| Non-cash interest expense | 20,584 |
| Non-cash accretion & amortization of short-term investments | -6,516 |
| Non-cash rent expense | 428 |
| Change in fair value of embedded derivative liability | -910 |
| Gain on settlement of forward contract | 0 |
| Acquired ipr&d assets classified as investing activities | 0 |
| Other non-cash items | -90 |
| Accounts receivable | 7,570 |
| Inventory | 7,474 |
| Prepaid expenses and other current assets | 6,327 |
| Deferred revenue | -1,092 |
| Other long-term assets, net | 397 |
| Accounts payable, accrued expenses and other liabilities | 21,892 |
| Net cash used in operating activities | -115,675 |
| Purchases of short-term investments | 348,669 |
| Maturities of short-term investments | 252,469 |
| Acquisition of ipr&d assets | 40,000 |
| Purchases of property and equipment | 953 |
| Net cash used in investing activities | -137,153 |
| Repayment of deferred royalty obligation | 19,917 |
| Proceeds from issuance of common stock upon completion of public offering, net of offering costs | 188,657 |
| Proceeds from the exercise of stock options | 13,604 |
| Proceeds from issuance of common stock from espp | 1,584 |
| Net proceeds from issuance of common stock | 34,035 |
| Proceeds from royalty financing agreement, net of issuance costs | 0 |
| Gain on settlement of forward contract | 0 |
| Proceeds from series a preferred stock, net of issuance costs | 0 |
| Net cash provided by financing activities | 217,963 |
| Effect of exchange rates on cash | 87 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -34,778 |
| Cash, cash equivalents and restricted cash at beginning of period | 89,601 |
| Cash, cash equivalents and restricted cash at end of period | 54,823 |
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)